China’s top drug regulator granted on 29 June a marketing green light to what appears set to be the world’s first immune checkpoint inhibitor-based bispecific antibody to be commercialized, as other pharma firms in the country remain mired in an increasingly overcrowded domestic market for anti-PD-1/L1 antibodies.
Hong Kong-listed Akeso Inc. gained a conditional approval for its PD-1/CTLA-4-targeting bispecific Kaitanni (cadonilimab; AK104) from the National Medical...